Overview
PRAX market data
Price History
PRAX price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for PRAX. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
Goldman Sachs Initiates Coverage On Praxis Precision Medicine with Buy Rating, Announces Price Target of $447Benzinga · Jul 13, 2026, 9:41 AM
8-K filing — Praxis Precision Medicines, Inc. (PRAX)SEC EDGAR · Jul 7, 2026, 9:05 PM
Praxis Precision Medicines And Remagine Labs Announce Research Collaboration And License Agreement To Develop Iontophoretic Transdermal Patch For Delivery Of Ulixacaltamide For Essential TremorBenzinga · Jul 7, 2026, 12:10 PM
Praxis Precision Medicines Announces FDA Extends PDUFA Date To December 27, 2026 For Relutrigine Following Major Amendment Submission; No New Clinical Or Safety Concerns CitedBenzinga · Jun 29, 2026, 8:40 PM
Applied Materials To Rally Around 20%? Here Are 10 Top Analyst Forecasts For MondayBenzinga · Jun 29, 2026, 1:05 PM
Praxis' Seizure Drug Move Towards Faster Development After Positive Trial ResultsBenzinga · Jun 22, 2026, 5:30 PM
Praxis Precision Medicines Receives Breakthrough Therapy Designation From FDA For Elsunersen To Treat Seizures Associated With SCN2A Development And Epileptic EncephalopathyBenzinga · Jun 22, 2026, 12:10 PM
RBC Capital Initiates Coverage On Praxis Precision Medicine with Outperform Rating, Announces Price Target of $449Benzinga · Jun 18, 2026, 1:45 PM
Oppenheimer Maintains Outperform on Praxis Precision Medicine, Lowers Price Target to $650Benzinga · Jun 2, 2026, 5:34 PM
Truist Securities Maintains Buy on Praxis Precision Medicine, Lowers Price Target to $616Benzinga · Jun 2, 2026, 5:03 PM